Skip to main content


Figure 4 | BMC Cancer

Figure 4

From: Access to care issues adversely affect breast cancer patients in Mexico: oncologists’ perspective

Figure 4

Patterns of therapy for HER2+ disease. For patients with tumors that are HER2+, ER+, less than 1 cm in size and node negative, 54% of physicians recommended trastuzumab, 36% recommended chemotherapy and 79% recommended endocrine therapy. For patients’ tumors that are HER2+, ER-, greater than 1 cm in size, and node negative, 78% of physicians recommended trastuzumab, 81% recommended chemotherapy, and 13% recommended endocrine therapy. Participants could select multiple therapy options to describe their treatment of HER2+ patients.

Back to article page